Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Why is Tesla’s $1 trillion pay deal controversial? How is the government shutdown impacting US flights? What caused the surge in US job layoffs? Why did Qatar Airways sell its Cathay Pacific stake? How are AI advancements affecting corporate layoffs? What’s behind the FAA’s 10% flight reduction plan? How did Democrats’ election wins affect markets?

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

benzinga.com/analyst-stock-ratings/upgrades/25/11/48599618/terns-pharmaceuticals-leukemia-drug-seen-as-potential-disruptor-in-cml-treatment-l

Terns Pharmaceuticals Inc. (NASDAQ:TERN) stock is trading higher on Monday, with a session volume of 24.36 million, compared to its average volume of 1.31 million, according to Benzinga Pro.
The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with…

This story appeared on benzinga.com, 2025-11-03 18:05:11.